Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of BioCentury Extra, The Daily News: Financial News

BioCentury Extra, The Daily News Current Issue
  • FINANCIAL NEWS: OncoGenex planning follow-on

    OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) said late Thursday it is planning a follow-on underwritten by Leerink; Stifel Nicolaus Weisel; Lazard; and William Blair. Further details were not disclosed. OncoGenex was up…

    Published on 3/15/2012
  • FINANCIAL NEWS: Sofinnova to establish Irish beachhead with $37.5M

    Enterprise Ireland and the National Pensions Reserve Fund committed a total of $37.5 million to Sofinnova Ventures, which will establish a presence in Ireland. The commitment was made via the Innovation Fund Ireland …

    Published on 3/15/2012
  • FINANCIAL NEWS: Welsh Life Sciences Fund closes L50M

    The Welsh Government has committed L50 million ($78.4 million) for its Welsh Life Sciences Fund. The government is seeking contributions from investors to give the fund a total of L100 million ($156.8 million). Chris …

    Published on 3/15/2012
  • FINANCIAL NEWS: Kala raises $6.2 million

    Kala Pharmaceuticals Inc. (Waltham, Ma.) raised an additional $6.2 million in seed financing, bringing the total raised to $11.2 million. New investor Lighthouse Capital Partners joined existing investors Lux Capital; …

    Published on 3/14/2012
  • FINANCIAL NEWS: Medivation raises $225M in note deal

    Medivation Inc. (NASDAQ:MDVN) raised $225 million in a bumped-up offering of 2.625% senior convertible notes due April 1, 2017. The notes initially convert at $102.47 per share, which is a 40% premium to Medivation's …

    Published on 3/14/2012
  • FINANCIAL NEWS: Salix raises $600M in note deal

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) raised $600 million in a bumped-up offering of 1.5% senior convertible notes due March 15, 2019. The notes initially convert at $65.81 per share, which is a 35% premium to Salix'…

    Published on 3/13/2012
  • FINANCIAL NEWS: Anthera plummets after discontinuing development of varespladib

    Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) fell $2.86 (45%) to $3.56 on Monday after announcing late Friday that it will discontinue development of cardiovascular compound varespladib for all indications. The secretory …

    Published on 3/12/2012
  • FINANCIAL NEWS: HemaQuest raises $13M in series B extension

    HemaQuest Pharmaceuticals Inc. (San Diego, Calif.) raised $13 million in an extension of a series B round, bringing the total raised in the round to $29 million. Existing investors Aberdare Ventures; De Novo Ventures; …

    Published on 3/12/2012
  • FINANCIAL NEWS: Medivation planning $175M note offering

    Medivation Inc. (NASDAQ:MDVN) proposed to sell $175 million in unsecured convertible senior notes due April 1, 2017. Citigroup is the sole book-running manager. Details were not disclosed. Medivation, which made the …

    Published on 3/12/2012
  • FINANCIAL NEWS: Piper Jaffray raising new fund

    Piper Jaffray is raising $100 million for its new private equity fund, Piper Jaffray Merchant Banking Fund I L.P., according to an SEC filing on March 7. The investment bank and asset management firm could not be …

    Published on 3/12/2012
  • FINANCIAL NEWS: Salix planning $500M note deal

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) proposed to sell $500 million of senior convertible notes due 2019. The notes will be convertible into cash, shares or a combination of both at Salix's election. The company …

    Published on 3/12/2012
  • FINANCIAL NEWS: Aastrom raises $40 million

    Aastrom Biosciences Inc. (NASDAQ:ASTM) raised $40 million through the sale of 12,300 shares of series B convertible preferred stock at $3,250 in a private placement to Eastern Capital. Each series B preferred stock …

    Published on 3/9/2012
  • FINANCIAL NEWS: Kolltan raises $25 million

    Kolltan Pharmaceuticals Inc. (New Haven, Conn.) raised $25 million in a series C round. Details were not disclosed. The company is developing mAbs and small molecules that target tyrosine kinase receptors to treat …

    Published on 3/9/2012
  • FINANCIAL NEWS: Amylin raises $203.1 million in follow-on

    Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) raised $203.1 million through the sale of 13 million shares at $15.62 in a follow-on underwritten by Credit Suisse. The company proposed the offering late Wednesday, when its …

    Published on 3/8/2012
  • FINANCIAL NEWS: Bellicum raises $10 million in series B

    Bellicum Pharmaceuticals Inc. (Houston, Texas) raised $10 million in the first tranche of a planned $20 million series B round. Undisclosed existing investors participated along with new investors, including AVG …

    Published on 3/8/2012
  • FINANCIAL NEWS: Elan divesting Alkermes shares

    Elan Corp. plc (NYSE:ELN) divested a 16% stake, or about $346.5 million, in Alkermes plc (NASDAQ:ALKS). Elan sold 21 million Alkermes shares at $16.50 in a registered offering underwritten by Citigroup; Jefferies; …

    Published on 3/8/2012
  • FINANCIAL NEWS: Sosei planning private placement

    Sosei Co. Ltd. plans to raise Y300 million ($3.7 million) through the sale of 300 preferred shares at Y1 million in a private placement to JAFCO. Additionally, Sosei has until March 31, 2014 to request an additional …

    Published on 3/8/2012
  • FINANCIAL NEWS: Amylin proposes follow-on

    Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) proposed late Wednesday to sell 13 million shares in a follow-on underwritten by Credit Suisse. If sold at Amylin's close of $16.17 on Wednesday, the company would raise $210.2 …

    Published on 3/7/2012
  • FINANCIAL NEWS: Discovery Laboratories gains on Surfaxin approval

    Discovery Laboratories Inc. (NASDAQ:DSCO) gained as much as 44% on Wednesday before closing up 9%, or $0.33, to $4.08 after FDA approved Surfaxin lucinactant late Tuesday to prevent respiratory distress syndrome in …

    Published on 3/7/2012
  • FINANCIAL NEWS: OpGen announces $17M C round

    Genomics company OpGen Inc. (Gaithersburg, Md.) announced a planned series C round of up to $17 million from new and existing investors. Harris & Harris Group and Cross Creek Capital are new investors. Highland Capital …

    Published on 3/7/2012
  • FINANCIAL NEWS: Phosphate Therapeutics raises EUR 10.5 million

    Phosphate Therapeutics Ltd. (Newcastle, U.K.) raised EUR 10.5 million ($13.9 million) from Inventages Venture Capital and received exclusive, worldwide rights to phosphate binder PT20 from U.K.'s Medical Research …

    Published on 3/7/2012
  • FINANCIAL NEWS: Promedior raises $21.5 million in series D

    Promedior Inc. (Malvern, Pa.) raised $21.5 million in the first close of a series D round led by new investor Fibrotec Ventures. All of Promedior's existing investors participated, including Morgenthaler Ventures; …

    Published on 3/7/2012
  • FINANCIAL NEWS: Provista Diagnostics raises $5M in A round

    Provista Diagnostics Inc. (Phoenix, Ariz.) raised $5 million in a series A round from a group of 18 institutional and individual investors, including the Louis-Dreyfus Family Office; Groton Partners; and MacOne. …

    Published on 3/7/2012
  • FINANCIAL NEWS: Aragon raises $42M in series C

    Aragon Pharmaceuticals Inc. (San Diego, Calif.) raised $42 million in a series C round led by new investor Topspin Fund. Existing investors Aisling Capital; OrbiMed; and The Column Group participated. Topspin's Leo …

    Published on 3/6/2012
  • FINANCIAL NEWS: Oncothyreon off as Stimuvax NSCLC data delayed

    Oncothyreon Inc. (NASDAQ:ONTY) fell $3.34 (40%) to $5.07 on Tuesday on news that data from the Phase III START trial of Stimuvax in non-small cell lung cancer will not be available until early 2013, instead of 2H12 as …

    Published on 3/6/2012

< Previous   1  2  3  4  5  6  7  8  9  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.